SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (786)4/9/2003 12:44:38 AM
From: tuck  Read Replies (1) | Respond to of 1005
 
GenVec has one AACR abstract that doesn't amount to much. ASCO is going to be the news driver near term. I was thinking of taking profits at the next resistance point for BLUE HP. I flipped mine a bit early, but won't complain about a profit. Speaking of gene therapy companies, I've been keeping my eye on INGN, but not closely. Apparently they don't have much going wrt AACR, but perhaps they might for ASCO? What do you know?

OT re GERN. I was very very bearish over $6.50. I discussed it fairly extensively on my short thread recently, on a suggestion from Nigel. I asked some day traders where they thought it would top out, and they said $9.00. So I waited, though was tempted when it got over $7, and have been kicking myself for not following my own instincts and shorting it there. Also ranted on T/FIF about not flipping it, but perhaps Rick will make something out of it in the long haul. He usually does. Now, with GERN in the low $5s, I'm neutral. Interesting the amount of the financing is about equal to the amount of outstanding converts.

I don't think they'll have much up their sleeve for ASCO; I think they've shot their PR wad for a while. They might manage a minor outlicensing deal here & there on their nuclear transfer, liver cell line, or stem cell IP. But I doubt anything significant for a while. As such, I would expect retracement. You can probably pick the supports better than I.

Cheers, Tuck